Circulating MDSCs are correlated with decreased responses to immunotherapy in melanoma patients [141,142], and were reported to promote tumor growth by producing immunosuppressive molecules in TME, such as IL-10, and reactive oxygen species (ROS), as well as expressing cell surface receptors, such as PD-L1 [143,144]. The gene discussed is CD274; the disease is neoplasm.